Shin Poong Pharm.Co.Ltd. (019170) - Net Assets
Based on the latest financial reports, Shin Poong Pharm.Co.Ltd. (019170) has net assets worth ₩264.20 Billion KRW (≈ $179.05 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩341.59 Billion ≈ $231.49 Million USD) and total liabilities (₩77.39 Billion ≈ $52.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Shin Poong Pharm.Co.Ltd. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩264.20 Billion |
| % of Total Assets | 77.34% |
| Annual Growth Rate | 5.22% |
| 5-Year Change | -31.05% |
| 10-Year Change | 32.45% |
| Growth Volatility | 18.21 |
Shin Poong Pharm.Co.Ltd. - Net Assets Trend (2003–2024)
This chart illustrates how Shin Poong Pharm.Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore Shin Poong Pharm.Co.Ltd. total assets for the complete picture of this company's asset base.
Annual Net Assets for Shin Poong Pharm.Co.Ltd. (2003–2024)
The table below shows the annual net assets of Shin Poong Pharm.Co.Ltd. from 2003 to 2024. For live valuation and market cap data, see 019170 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩258.09 Billion ≈ $174.90 Million |
-4.69% |
| 2023-12-31 | ₩270.78 Billion ≈ $183.51 Million |
-18.13% |
| 2022-12-31 | ₩330.76 Billion ≈ $224.15 Million |
-6.71% |
| 2021-12-31 | ₩354.56 Billion ≈ $240.28 Million |
-5.28% |
| 2020-12-31 | ₩374.33 Billion ≈ $253.68 Million |
+79.00% |
| 2019-12-31 | ₩209.13 Billion ≈ $141.72 Million |
+0.79% |
| 2018-12-31 | ₩207.48 Billion ≈ $140.61 Million |
-1.25% |
| 2017-12-31 | ₩210.11 Billion ≈ $142.39 Million |
-3.11% |
| 2016-12-31 | ₩216.85 Billion ≈ $146.96 Million |
+11.28% |
| 2015-12-31 | ₩194.86 Billion ≈ $132.05 Million |
+1.75% |
| 2014-12-31 | ₩191.51 Billion ≈ $129.79 Million |
+0.38% |
| 2013-12-31 | ₩190.79 Billion ≈ $129.29 Million |
+1.09% |
| 2012-12-31 | ₩188.73 Billion ≈ $127.90 Million |
+4.93% |
| 2011-12-31 | ₩179.86 Billion ≈ $121.89 Million |
+19.59% |
| 2010-12-31 | ₩150.39 Billion ≈ $101.92 Million |
+3.50% |
| 2009-12-31 | ₩145.31 Billion ≈ $98.48 Million |
+13.58% |
| 2008-12-31 | ₩127.93 Billion ≈ $86.70 Million |
+12.41% |
| 2007-12-31 | ₩113.81 Billion ≈ $77.12 Million |
+7.09% |
| 2006-12-31 | ₩106.28 Billion ≈ $72.02 Million |
+8.83% |
| 2005-12-31 | ₩97.65 Billion ≈ $66.18 Million |
+11.78% |
| 2004-12-31 | ₩87.36 Billion ≈ $59.20 Million |
-1.39% |
| 2003-12-31 | ₩88.59 Billion ≈ $60.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shin Poong Pharm.Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3894326103000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩38.94 Billion | 15.16% |
| Other Components | ₩217.88 Billion | 84.84% |
| Total Equity | ₩256.82 Billion | 100.00% |
Shin Poong Pharm.Co.Ltd. Competitors by Market Cap
The table below lists competitors of Shin Poong Pharm.Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASTON MART.LA.UADR LS-001
F:A5S0
|
$390.66 Million |
|
BP p.l.c
LSE:BP-B
|
$390.70 Million |
|
PHOENIX N AG
SW:PMN
|
$390.72 Million |
|
Shinhsiung Natural Gas
TWO:8908
|
$390.76 Million |
|
Mercurity Fintech Holding Inc ADR
NASDAQ:MFH
|
$390.29 Million |
|
Beijing Jiaoda Signal Technology
SHE:300851
|
$390.28 Million |
|
Altek Corp
TW:3059
|
$389.97 Million |
|
Shenyang Huitian Thermal Power Co Ltd
SHE:000692
|
$389.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shin Poong Pharm.Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 269,585,828,030 to 256,820,523,460, a change of -12,765,304,570 (-4.7%).
- Net loss of 15,387,261,000 reduced equity.
- Other factors increased equity by 2,621,956,430.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-15.39 Billion | -5.99% |
| Other Changes | ₩2.62 Billion | +1.02% |
| Total Change | ₩- | -4.74% |
Book Value vs Market Value Analysis
This analysis compares Shin Poong Pharm.Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.67x to 2.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4372.79 | ₩11690.00 | x |
| 2018-12-31 | ₩4303.11 | ₩11690.00 | x |
| 2019-12-31 | ₩4338.83 | ₩11690.00 | x |
| 2020-12-31 | ₩7577.91 | ₩11690.00 | x |
| 2021-12-31 | ₩7174.44 | ₩11690.00 | x |
| 2022-12-31 | ₩6689.68 | ₩11690.00 | x |
| 2023-12-31 | ₩5471.49 | ₩11690.00 | x |
| 2024-12-31 | ₩5212.40 | ₩11690.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shin Poong Pharm.Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.96%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.33x
- Recent ROE (-5.99%) is below the historical average (3.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 15.04% | 10.49% | 0.76x | 1.89x | ₩4.43 Billion |
| 2004 | 1.53% | 0.94% | 0.81x | 2.01x | ₩-7.38 Billion |
| 2005 | 12.08% | 7.71% | 0.80x | 1.95x | ₩2.03 Billion |
| 2006 | 20.57% | 13.74% | 0.79x | 1.90x | ₩11.21 Billion |
| 2007 | 7.33% | 5.02% | 0.76x | 1.91x | ₩-3.03 Billion |
| 2008 | 8.91% | 6.04% | 0.70x | 2.11x | ₩-1.40 Billion |
| 2009 | 13.71% | 9.15% | 0.70x | 2.14x | ₩5.37 Billion |
| 2010 | 13.67% | 8.84% | 0.72x | 2.14x | ₩5.51 Billion |
| 2011 | 13.07% | 10.22% | 0.61x | 2.11x | ₩5.51 Billion |
| 2012 | 7.21% | 6.14% | 0.58x | 2.01x | ₩-5.26 Billion |
| 2013 | 2.69% | 2.38% | 0.54x | 2.09x | ₩-13.92 Billion |
| 2014 | 1.65% | 1.44% | 0.54x | 2.14x | ₩-15.96 Billion |
| 2015 | 0.76% | 0.75% | 0.48x | 2.12x | ₩-17.87 Billion |
| 2016 | -8.59% | -9.58% | 0.47x | 1.92x | ₩-40.25 Billion |
| 2017 | 0.43% | 0.49% | 0.48x | 1.84x | ₩-20.08 Billion |
| 2018 | 1.36% | 1.50% | 0.49x | 1.85x | ₩-17.84 Billion |
| 2019 | 2.56% | 2.81% | 0.50x | 1.83x | ₩-15.49 Billion |
| 2020 | 1.34% | 2.53% | 0.41x | 1.30x | ₩-32.33 Billion |
| 2021 | -3.28% | -6.12% | 0.48x | 1.11x | ₩-46.93 Billion |
| 2022 | -10.73% | -16.90% | 0.58x | 1.10x | ₩-68.34 Billion |
| 2023 | -21.26% | -28.63% | 0.57x | 1.30x | ₩-84.28 Billion |
| 2024 | -5.99% | -6.96% | 0.65x | 1.33x | ₩-41.07 Billion |
Industry Comparison
This section compares Shin Poong Pharm.Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shin Poong Pharm.Co.Ltd. (019170) | ₩264.20 Billion | 15.04% | 0.29x | $390.33 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more